|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0170 AUD | +6.25% |
|
+41.67% | +13.33% |
| 05-28 | Acrux licenses Lenzetto for Australian market for A$5.4 million | RE |
| 05-27 | Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia | RE |
| Market Cap | 8.73M 6.17M 5.31M 4.89M 4.59M 8.63M 583M 57.72M 22.51M 287M 23.13M 22.64M 989M | P/E Ratio 2024 |
-3.44x | P/E Ratio 2025 | -0.95x |
|---|---|---|---|---|---|
| Enterprise Value | 11.5M 8.13M 7M 6.44M 6.05M 11.37M 769M 76.06M 29.66M 378M 30.48M 29.84M 1.3B | EV / Sales 2024 |
4.09x | EV / Sales 2025 | 7.81x |
| Free-Float |
78.27% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/05/22 | Acrux : Application for quotation of securities - ACR | PU |
| 14/04/22 | Acrux : Application for quotation of securities - ACR | PU |
| 15/03/22 | Acrux : Application for quotation of securities - ACR | PU |
| 25/02/22 | Acrux : Updated Board Charter | PU |
| 25/02/22 | Acrux : Application for quotation of securities - ACR | PU |
| 1 day | +6.25% | ||
| 1 week | +41.67% | ||
| Current month | +41.67% | ||
| 1 month | +54.55% | ||
| 3 months | +41.67% | ||
| 6 months | +6.25% | ||
| Current year | +13.33% |
| 1 week | 0.01 | 0.02 | |
| 1 month | 0.01 | 0.02 | |
| Current year | 0.01 | 0.02 | |
| 1 year | 0.01 | 0.02 | |
| 3 years | 0.01 | 0.1 | |
| 5 years | 0.01 | 0.16 | |
| 10 years | 0.01 | 0.84 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Warmbrunn
CEO | Chief Executive Officer | - | 31/05/2025 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 20/06/2021 |
| Chief Tech/Sci/R&D Officer | - | 14/02/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ross Dobinson
CHM | Chairman | 74 | 31/12/2005 |
Timothy Oldham
BRD | Director/Board Member | - | 30/09/2013 |
Geoff Brooke
BRD | Director/Board Member | 70 | 31/05/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +6.25% | +41.67% | -22.73% | -63.83% | 5.82M | ||
| -0.29% | +0.67% | +6.69% | +82.18% | 45.85B | ||
| +1.27% | -1.80% | +42.88% | +87.04% | 33.63B | ||
| -0.59% | -1.06% | -8.77% | +37.57% | 11.81B | ||
| -0.86% | -0.82% | +10.64% | +96.43% | 11.59B | ||
| +1.54% | +3.12% | +40.43% | +132.60% | 9.28B | ||
| -1.73% | -1.89% | +18.15% | +42.12% | 7.33B | ||
| -0.26% | +0.49% | +44.71% | -15.55% | 6.65B | ||
| +0.00% | -0.91% | +29.15% | +235.70% | 6.44B | ||
| -3.10% | -2.79% | -44.79% | -6.76% | 5.16B | ||
| Average | +0.22% | +3.07% | +11.64% | +62.75% | 13.77B | |
| Weighted average by Cap. | -0.03% | -0.37% | +18.37% | +81.13% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 5.09M 3.6M 3.1M 2.85M 2.68M 5.03M 340M 33.68M 13.13M 167M 13.5M 13.21M 577M | 1.19M 841K 724K 667K 626K 1.18M 79.54M 7.87M 3.07M 39.08M 3.16M 3.09M 135M |
| Net income | -5.8M -4.1M -3.53M -3.25M -3.05M -5.73M -388M -38.37M -14.96M -190M -15.38M -15.05M -657M | -5.94M -4.2M -3.62M -3.33M -3.13M -5.88M -397M -39.33M -15.33M -195M -15.76M -15.43M -674M |
| Net Debt | 759K 536K 462K 425K 399K 750K 50.73M 5.02M 1.96M 24.93M 2.01M 1.97M 86.04M | 2.77M 1.96M 1.69M 1.55M 1.46M 2.74M 185M 18.34M 7.15M 91.04M 7.35M 7.19M 314M |
Employees
43
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/06/26 | 0.0170 $ | +6.25% | 1,027,700 |
| 15/06/26 | 0.0160 $ | -5.88% | 124,024 |
| 12/06/26 | 0.0170 $ | -5.56% | 2,127,316 |
| 11/06/26 | 0.0180 $ | +12.50% | 3,458,763 |
| 10/06/26 | 0.0160 $ | +33.33% | 5,602,843 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ACR Stock
Select your edition
All financial news and data tailored to specific country editions
















